Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0001104659-25-042584
Filing Date
2025-04-30
Accepted
2025-04-30 16:34:29
Documents
18
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 FORM-10-K/A tmb-20241231x10ka.htm   iXBRL 10-K/A 893397
2 EXHIBIT-31.3 tmb-20241231xex31d3.htm EX-31.3 6001
3 EXHIBIT-31.4 tmb-20241231xex31d4.htm EX-31.4 5255
7 GRAPHIC tmb-20241231x10ka001.jpg GRAPHIC 9063
  Complete submission text file 0001104659-25-042584.txt   1286165

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA tmb-20241231.xsd EX-101.SCH 3667
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE tmb-20241231_lab.xml EX-101.LAB 23787
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tmb-20241231_pre.xml EX-101.PRE 15826
21 EXTRACTED XBRL INSTANCE DOCUMENT tmb-20241231x10ka_htm.xml XML 11962
Mailing Address 777 TOWNSHIP LINE ROAD SUITE 300 YARDLEY PA 19067
Business Address 777 TOWNSHIP LINE ROAD SUITE 300 YARDLEY PA 19067 267-364-3500
OptiNose, Inc. (Filer) CIK: 0001494650 (see all company filings)

EIN.: 421771610 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 001-38241 | Film No.: 25896052
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)